ReviewImmunity2022
Inducing broad-based immunity against viruses with pandemic potential.
Review in Immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Comprehensive mapping of human CD4Cell reports. Medicine · 2026Article
- Decoding the human CD4Cell reports. Medicine · 2026Article
- Integrated reiterative pipeline for rapid epitope-based pan-alphavirus vaccines.Science advances · 2026Article
- Article
- A Roadmap Towards the Identification and Validation of Conserved T Cell Epitope Regions in Viral Pathogen Families with Pandemic Potential.Current pharmaceutical biotechnology · 2026Article
- Robust polyfunctional CD8The Journal of general virology · 2025Article
- Identification of immunogenic and cross-reactive chikungunya virus epitopes for CD4Nature communications · 2025Article
- Article
- Article
- Heterologous ORFV-Ad26 vaccination broadens antibody breadth and amplifies cellular immunity against SARS-CoV-2 spike.Frontiers in immunology · 2025Article
- Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2.JCI insight · 2024Article
- The Influence of Cross-Reactive T Cells in COVID-19.Biomedicines · 2024Review
- Design of universal Ebola virus vaccine candidates via immunofocusing.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Bringing immunofocusing into focus.NPJ vaccines · 2024Review
- Correlative CD4 and CD8 T-cell immunodominance in humans and mice: Implications for preclinical testing.Cellular & molecular immunology · 2023Article
- A Prototype-Pathogen Approach for the Development of Flavivirus Countermeasures.The Journal of infectious diseases · 2023Review
- Design of universal Ebola virus vaccine candidatesbioRxiv : the preprint server for biology · 2023Article
- An update on studies characterizing adaptive immune responses in SARS-CoV-2 infection and COVID-19 vaccination.International immunology · 2023Article
- The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic.Pathogens (Basel, Switzerland) · 2023Review
- Targets and cross-reactivity of human T cell recognition of common cold coronaviruses.Cell reports. Medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The brutal toll of another viral pandemic can be blunted by investing now in research that uncovers mechanisms of broad-based immunity so we may have vaccines and therapeutics at the ready. We do not know exactly what pathogen may trigger the next wave or next pandemic. We do know, however, that the human immune system must respond and must be bolstered with effective vaccines and other therapeutics to preserve lives and livelihoods. These countermeasures must focus on features conserved among families of pathogens in order to be responsive against something yet to emerge. Here, we focus on immunological approaches to mitigate the impact of the next emerging virus pandemic by developing vaccines that elicit both broadly protective antibodies and T cells. Identifying human immune mechanisms of broad protection against virus families with pandemic potential will be our best defense for humanity in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.